Daily Roundup

BIO.ASX EGL.ASX GQG.ASX KYP.ASX TLX.ASX

Biome Australia Delivers Record Sales in FY25

Biome Australia Ltd (ASX:BIO) has reported a stellar performance, with unaudited full-year sales revenue reaching a record ~$18.4 million for the 2025 financial year (FY25). This represents a remarkable 41% increase compared to the previous year, driven by a standout fourth quarter and an exceptional June.

In Q4 FY25, Biome's sales revenue exceeded $5 million, a 33% jump from the same period in the prior year. The company then capped off the year with record monthly sales of ~$2.1 million in June, a 50% surge from the previous corresponding period.

Biome's CEO expressed satisfaction with the company's achievements, noting that the robust results reflect the strong demand for its products and the team's execution. With this momentum, the company is well-positioned to continue its growth trajectory and solidify its market leadership.

Environmental Group Secures $1.9M PFAS Treatment Contract

The Environmental Group Limited (ASX: EGL) has landed a significant contract, securing a $1.9 million order to design and construct a new PFAS treatment plant. This project represents a major milestone for EGL, as it marks the first commercial deployment of the company's proprietary PFAS treatment technology.

The facility will treat both water and soil contaminated with per- and polyfluoroalkyl substances (PFAS), a persistent environmental pollutant. EGL's solution utilizes its innovative foam fractionation technology, engineered to safely and effectively extract PFAS compounds without the need for chemical pre-treatment.

EGL believes the PFAS treatment market is a rapidly growing area, driven by increasing environmental regulations and the growing awareness of the toxic nature of PFAS substances. This contract further strengthens EGL's position as a leader in providing sustainable environmental technology solutions.

GQG Partners Reports Record FUM, but Faces Relative Underperformance

GQG Partners Inc. (ASX: GQG) has reached a new high in funds under management (FUM), reporting a record $172.4 billion as of June 30, 2025. This represents an increase of $3.9 billion from the previous month and $8.0 billion year-to-date.

While GQG's FUM has reached new heights, the company noted that it has continued to position its portfolios defensively, resulting in relative underperformance across all strategies compared to their respective benchmarks during the second quarter. GQG stated that it remains focused on protecting client capital in the face of ongoing market volatility, corporate earnings uncertainty, and macroeconomic challenges.

Despite the short-term relative underperformance, GQG reaffirmed its defensive positioning, noting that management fees continue to comprise the vast majority of its net revenue, and that the management team remains highly aligned with shareholders and clients.

Kinatico Delivers Strong FY25 Results, Driven by SaaS Growth

Kinatico Ltd, a leading Australian RegTech company, has reported impressive financial results for the 2025 financial year. The company's total revenue reached $32.1 million, a 12% increase compared to the previous year, with a standout performance in its SaaS business.

Kinatico's SaaS revenue surged 54% year-over-year to $14.9 million, and the company's Q4 FY25 SaaS revenue run rate reached an annualized $17.5 million, up 57% from the previous corresponding period. The company also remained cash accretive for the year, with a closing cash and cash equivalents balance of $10.2 million.

Kinatico's CEO expressed satisfaction with the excellent results, highlighting the company's focus on building its new Kinatico Compliance solution, which is expected to further enhance the company's SaaS growth. Kinatico continues to solidify its position as the pre-eminent background screening brand in Australasia and is planning its global expansion of its growing suite of RegTech solutions.

Telix Pharmaceuticals Secures Permanent HCPCS Code for Gozellix

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) has announced a significant milestone for its next-generation PSMA PET imaging agent, Gozellix®. The company has been granted a permanent Healthcare Common Procedure Coding System (HCPCS) code by the U.S. Centers for Medicare & Medicaid Services (CMS), effective from October 1, 2025.

The assignment of the HCPCS Level II code A9616 will enable provider billing and reimbursement for Gozellix, a crucial step in supporting the clinical adoption and expanded access to PSMA PET imaging for prostate cancer patients. Gozellix's extended shelf-life and flexible production options help overcome many of the logistical barriers that have historically limited access to this important diagnostic tool.

Telix believes the permanent HCPCS code will further strengthen Gozellix's position and drive increased utilization of PSMA PET imaging in the detection and management of prostate cancer across the United States.